fluoxetine has been researched along with Panic Attacks in 70 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder." | 9.09 | Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. ( Lydiard, RB; Michelson, D; Pollack, M; Tamura, R; Tepner, R; Tollefson, G, 1999) |
| "Ten patients with DSM-III-R panic disorder were treated openly with fluoxetine, 20-40 mg daily." | 9.09 | Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. ( Ballenger, JC; Brawman-Mintzer, O; Emmanuel, NP; Lydiard, RB; Ware, MR, 1999) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 9.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder." | 9.09 | Mirtazapine versus fluoxetine in the treatment of panic disorder. ( Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L, 2001) |
| "Patients with panic disorder were randomised to placebo or to fluoxetine initiated at 10 mg daily for 1 week and then increased to 20 mg daily." | 9.09 | Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. ( Allgulander, C; Dantendorfer, K; Knezevic, A; Maierhofer, D; Micev, V; Michelson, D; Paunovic, VR; Pemberton, SC; Sarkar, N; Skoglund, L; Timotijevic, I, 2001) |
| "Fluoxetine, particularly the 20-mg/day dose, was associated with more improvement than was placebo in patients with panic disorder across multiple symptom measures, including global improvement, total panic attack frequency, phobic symptoms, and functional impairment." | 9.08 | Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. ( Demitrack, MA; Hoog, SL; Lydiard, RB; Michelson, D; Pollack, MH; Tamura, RN; Tepner, R; Tollefson, GD, 1998) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 9.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| " Patients who discontinued fluoxetine tended to have panic disorder in addition to depression." | 9.07 | Use of low-dose fluoxetine in major depression and panic disorder. ( Lannon, RA; Lewis, TB; Louie, AK, 1993) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 7.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| "Blunted secretion of human GH in response to clonidine in patients with panic disorder persists despite clinical recovery." | 7.69 | Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. ( Cooper, T; Coplan, JD; Gorman, JM; Liebowitz, MR; Martinez, J; Papp, LA; Pine, D; Rosenblum, LA, 1995) |
| "The current case series is the first, to our knowledge, to suggest that the combination of a TCA and fluoxetine may provide a viable pharmacotherapeutic option for panic disorder patients who have failed to respond to an adequate trial of either a TCA or fluoxetine." | 7.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 6.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "Panic attacks are also precipitated by both the infusion of 0." | 5.40 | Evidence of a suffocation alarm system sensitive to clinically-effective treatments with the panicolytics clonazepam and fluoxetine. ( Müller, CJ; Schenberg, LC; Schimitel, FG; Tufik, S, 2014) |
| "To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder." | 5.09 | Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. ( Lydiard, RB; Michelson, D; Pollack, M; Tamura, R; Tepner, R; Tollefson, G, 1999) |
| "Ten patients with DSM-III-R panic disorder were treated openly with fluoxetine, 20-40 mg daily." | 5.09 | Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. ( Ballenger, JC; Brawman-Mintzer, O; Emmanuel, NP; Lydiard, RB; Ware, MR, 1999) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 5.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder." | 5.09 | Mirtazapine versus fluoxetine in the treatment of panic disorder. ( Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L, 2001) |
| "Patients with panic disorder were randomised to placebo or to fluoxetine initiated at 10 mg daily for 1 week and then increased to 20 mg daily." | 5.09 | Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. ( Allgulander, C; Dantendorfer, K; Knezevic, A; Maierhofer, D; Micev, V; Michelson, D; Paunovic, VR; Pemberton, SC; Sarkar, N; Skoglund, L; Timotijevic, I, 2001) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 5.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| "Fluoxetine, particularly the 20-mg/day dose, was associated with more improvement than was placebo in patients with panic disorder across multiple symptom measures, including global improvement, total panic attack frequency, phobic symptoms, and functional impairment." | 5.08 | Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. ( Demitrack, MA; Hoog, SL; Lydiard, RB; Michelson, D; Pollack, MH; Tamura, RN; Tepner, R; Tollefson, GD, 1998) |
| "Nine patients with panic disorders, previously shown to panic in response to intravenously administered lactate, and 10 control subjects underwent the Read rebreathing test by a 5-min inhalation of a 7% CO2/93% O2 mixture before and after 1 month of fluoxetine treatment." | 5.08 | Antipanic effect of fluoxetine measured by CO2 challenge test. ( Bocola, V; Fabbrini, G; Martucci, N; Paladini, C; Sollecito, A; Trecco, MD, 1998) |
| " Patients who discontinued fluoxetine tended to have panic disorder in addition to depression." | 5.07 | Use of low-dose fluoxetine in major depression and panic disorder. ( Lannon, RA; Lewis, TB; Louie, AK, 1993) |
| " Low-dose fluoxetine administered in the premenstrual phase deserves further attention for management of panic disorders in women." | 4.02 | Enhanced responsiveness to hypoxic panicogenic challenge in female rats in late diestrus is suppressed by short-term, low-dose fluoxetine: Involvement of the dorsal raphe nucleus and the dorsal periaqueductal gray. ( Batistela, MF; Frias, AT; Hernandes, PM; Lovick, TA; Vilela-Costa, HH; Zangrossi, H, 2021) |
| "The purpose of this study was to investigate the effects of the chronic administration of a racemic mixture of 8-prenylnaringenin (8-PN) on rats submitted to the elevated T-maze (ETM) model of generalized anxiety and panic disorders." | 3.80 | Molecular docking and panicolytic effect of 8-prenylnaringenin in the elevated T-maze. ( Abiko, LA; Audi, EA; Bagatin, MC; Basso, EA; Gauze, Gde F; Perego, LM; Seixas, FA; Silva, PR; Tozatti, CS; Yamazaki, DA, 2014) |
| "Chronic administration of antidepressants such as fluoxetine and imipramine increases the responsiveness of 5-HT(1A) receptors in dorsal periaqueductal grey matter (DPAG), a midbrain area consistently implicated in the pathogenesis of panic disorder." | 3.76 | Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine. ( Brandão, ML; Carvalho, MC; de Bortoli, VC; Pobbe, RL; Zangrossi, H; Zanoveli, JM, 2010) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 3.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| "The main objective of this report was to identify patient characteristics that led psychiatrists in an academic anxiety disorders clinic to make a decision about intensive treatment of patients with panic disorder with agoraphobia (PDA) with cognitive-behavioral therapy (CBT) alone, CBT plus a high-potency benzodiazepine (CBT+BZ) or CBT combined with BZ and an antidepressant, fluoxetine (CBT+BZ+AD)." | 3.72 | Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices. ( Kolar, D; Latas, M; Linden, M; Starcevic, V; Uhlenhuth, EH, 2004) |
| "Twenty-one pediatric subjects with diagnoses of autistic disorder or other pervasive developmental disorders, 6-15 years old and stabilized with a consistent dose of fluvoxamine or fluoxetine, were recruited for the study; 16 successfully completed the imaging protocol." | 3.71 | Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. ( Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002) |
| "A 39-year-old white woman with depression and panic attacks was being treated with fluoxetine, trazodone, clonazepam, and cimetidine." | 3.70 | Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. ( Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998) |
| "The current case series is the first, to our knowledge, to suggest that the combination of a TCA and fluoxetine may provide a viable pharmacotherapeutic option for panic disorder patients who have failed to respond to an adequate trial of either a TCA or fluoxetine." | 3.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Blunted secretion of human GH in response to clonidine in patients with panic disorder persists despite clinical recovery." | 3.69 | Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. ( Cooper, T; Coplan, JD; Gorman, JM; Liebowitz, MR; Martinez, J; Papp, LA; Pine, D; Rosenblum, LA, 1995) |
| "We present two patients with a history of chronic idiopathic urticaria occurring in conjunction with a panic disorder (DSM-IIIR), in whom both the urticaria and panic disorder responded favorably to a course of the selective serotonin reuptake inhibitor antidepressants fluoxetine and sertraline, respectively." | 3.69 | Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? ( Gupta, AK; Gupta, MA, 1995) |
| " Eighty of 230 patients who met the DSM-III-R criteria for panic disorder received, during the course of treatment, fluvoxamine (a selective serotonin reuptake inhibitor) at a dose level between 50-200 mg/day." | 3.68 | Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors. ( Fux, M; Taub, M; Zohar, J, 1993) |
| "Panic disorder is common in the general population with a prevalence of 1% to 4%." | 3.01 | Pharmacological treatments in panic disorder in adults: a network meta-analysis. ( Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A, 2023) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 2.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "Panic disorder is a prevalent psychiatric condition that often is chronic and rarely resolves without medical intervention." | 2.40 | Current concepts in the treatment of panic disorder. ( Sheehan, DV, 1999) |
| "Panic attacks are also precipitated by both the infusion of 0." | 1.40 | Evidence of a suffocation alarm system sensitive to clinically-effective treatments with the panicolytics clonazepam and fluoxetine. ( Müller, CJ; Schenberg, LC; Schimitel, FG; Tufik, S, 2014) |
| " However, although the NPS anxiolytic dose-response curve displayed the classical sigmoidal shape, the dose-response curve of the putative panicolytic-like effect was bell shaped with peak effect at 0." | 1.38 | Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. ( Calo, G; Guerrini, R; Pulga, A; Rizzi, A; Ruzza, C, 2012) |
| "Pretreatment with naloxone injected intra-DPAG antagonized both the panicolytic effect of chronic fluoxetine as well as that of 5-HT injected intra-DPAG." | 1.38 | The panicolytic-like effect of fluoxetine in the elevated T-maze is mediated by serotonin-induced activation of endogenous opioids in the dorsal periaqueductal grey. ( Audi, EA; Biesdorf, C; Graeff, FG; Roncon, CM; Santana, RG; Zangrossi, H, 2012) |
| " No threshold changes were observed following the long-term administration of the higher dose of either CLM or FLX." | 1.31 | Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat. ( Schenberg, LC; Vargas, LC, 2001) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.43) | 18.7374 |
| 1990's | 40 (57.14) | 18.2507 |
| 2000's | 17 (24.29) | 29.6817 |
| 2010's | 9 (12.86) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Batistela, MF | 1 |
| Vilela-Costa, HH | 1 |
| Frias, AT | 1 |
| Hernandes, PM | 1 |
| Lovick, TA | 1 |
| Zangrossi, H | 4 |
| Guaiana, G | 1 |
| Meader, N | 1 |
| Barbui, C | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 1 |
| Imai, H | 1 |
| Dias, S | 1 |
| Caldwell, DM | 1 |
| Koesters, M | 1 |
| Tajika, A | 1 |
| Bighelli, I | 1 |
| Pompoli, A | 1 |
| Cipriani, A | 1 |
| Dawson, S | 1 |
| Robertson, L | 1 |
| Argun, M | 1 |
| Gul, H | 1 |
| Çelebı, S | 1 |
| Elmalı, F | 1 |
| Narin, N | 1 |
| Maraschin, JC | 1 |
| Sestile, CC | 1 |
| Yabiku, CT | 1 |
| Roncon, CM | 2 |
| de Souza Fiaes, GC | 1 |
| Graeff, FG | 2 |
| Audi, EA | 3 |
| Schimitel, FG | 1 |
| Müller, CJ | 1 |
| Tufik, S | 1 |
| Schenberg, LC | 2 |
| Bagatin, MC | 1 |
| Tozatti, CS | 1 |
| Abiko, LA | 1 |
| Yamazaki, DA | 1 |
| Silva, PR | 1 |
| Perego, LM | 1 |
| Seixas, FA | 1 |
| Basso, EA | 1 |
| Gauze, Gde F | 1 |
| Annerbrink, K | 1 |
| Olsson, M | 1 |
| Hedner, J | 1 |
| Eriksson, E | 1 |
| DeVeaugh-Geiss, AM | 1 |
| West, SL | 1 |
| Miller, WC | 1 |
| Sleath, B | 1 |
| Kroenke, K | 1 |
| Gaynes, BN | 1 |
| Zanoveli, JM | 1 |
| Pobbe, RL | 1 |
| de Bortoli, VC | 1 |
| Carvalho, MC | 1 |
| Brandão, ML | 1 |
| Mochcovitch, MD | 1 |
| Nardi, AE | 1 |
| Biesdorf, C | 1 |
| Santana, RG | 1 |
| Pulga, A | 1 |
| Ruzza, C | 1 |
| Rizzi, A | 1 |
| Guerrini, R | 1 |
| Calo, G | 1 |
| Akarachkova, ES | 1 |
| Tabeeva, GR | 1 |
| Volkova, ZI | 1 |
| Dlusskaia, IG | 1 |
| Striuk, RI | 1 |
| Veĭn, AM | 1 |
| Boerner, RJ | 1 |
| Masuda, Y | 1 |
| Shimizu, T | 1 |
| Starcevic, V | 1 |
| Linden, M | 1 |
| Uhlenhuth, EH | 2 |
| Kolar, D | 1 |
| Latas, M | 1 |
| Vorob'eva, OV | 1 |
| Vasil'chikova, NV | 1 |
| Cyranowski, JM | 2 |
| Frank, E | 2 |
| Shear, MK | 2 |
| Swartz, H | 1 |
| Fagiolini, A | 2 |
| Scott, J | 1 |
| Kupfer, DJ | 2 |
| Hogg, S | 1 |
| Michan, L | 1 |
| Jessa, M | 1 |
| Tasci, I | 1 |
| Gupta, MA | 1 |
| Gupta, AK | 1 |
| Marshall, RD | 1 |
| Printz, D | 1 |
| Cardenas, D | 1 |
| Abbate, L | 1 |
| Liebowitz, MR | 2 |
| Coplan, JD | 4 |
| Papp, LA | 3 |
| Martinez, J | 3 |
| Pine, D | 3 |
| Rosenblum, LA | 3 |
| Cooper, T | 3 |
| Gorman, JM | 5 |
| Pecknold, JC | 1 |
| Luthe, L | 1 |
| Iny, L | 1 |
| Ramdoyal, D | 1 |
| Pollack, MH | 4 |
| Otto, MW | 1 |
| Kaspi, SP | 1 |
| Hammerness, PG | 1 |
| Rosenbaum, JF | 1 |
| Tiffon, L | 1 |
| Fux, M | 1 |
| Taub, M | 1 |
| Zohar, J | 1 |
| Louie, AK | 1 |
| Lewis, TB | 1 |
| Lannon, RA | 1 |
| Larson, EW | 1 |
| Nagy, LM | 1 |
| Morgan, CA | 1 |
| Southwick, SM | 1 |
| Charney, DS | 1 |
| Papp, L | 1 |
| Young, SJ | 1 |
| Sheehan, DV | 2 |
| Harnett-Sheehan, K | 1 |
| Oleshansky, MA | 1 |
| Labbate, LA | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Fairbanks, JM | 1 |
| Pine, DS | 1 |
| Tancer, NK | 1 |
| Dummit, ES | 1 |
| Kentgen, LM | 1 |
| Martin, J | 1 |
| Asche, BK | 1 |
| Klein, RG | 1 |
| Benazzi, F | 2 |
| Klein, DF | 1 |
| Kindler, S | 1 |
| Dolberg, OT | 1 |
| Cohen, H | 1 |
| Hirschmann, S | 1 |
| Kotler, M | 2 |
| Tiller, JW | 2 |
| Bouwer, C | 2 |
| Behnke, K | 2 |
| Dager, SR | 2 |
| Richards, T | 1 |
| Strauss, W | 1 |
| Artru, A | 1 |
| Bhatara, VS | 1 |
| Magnus, RD | 1 |
| Paul, KL | 1 |
| Preskorn, SH | 1 |
| Bocola, V | 1 |
| Trecco, MD | 1 |
| Fabbrini, G | 1 |
| Paladini, C | 1 |
| Sollecito, A | 1 |
| Martucci, N | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Nutt, DJ | 1 |
| Michelson, D | 3 |
| Lydiard, RB | 4 |
| Tamura, RN | 1 |
| Hoog, SL | 1 |
| Tepner, R | 2 |
| Demitrack, MA | 1 |
| Tollefson, GD | 1 |
| Cookson, J | 1 |
| Duffett, R | 1 |
| Emmanuel, NP | 1 |
| Ware, MR | 1 |
| Brawman-Mintzer, O | 1 |
| Ballenger, JC | 1 |
| Pollack, M | 1 |
| Tamura, R | 1 |
| Tollefson, G | 1 |
| Yager, J | 1 |
| Siegfreid, SL | 1 |
| DiMatteo, TL | 1 |
| Ohman, R | 1 |
| Hägg, S | 1 |
| Carleborg, L | 1 |
| Spigset, O | 1 |
| Zaitsev, I | 1 |
| Rucci, P | 1 |
| Endicott, J | 1 |
| Grochocinski, VJ | 1 |
| Houck, P | 1 |
| Maser, JD | 1 |
| Cassano, GB | 1 |
| Schatzberg, AF | 1 |
| Matuzas, W | 1 |
| Warner, TD | 1 |
| Paine, S | 1 |
| Soini, M | 1 |
| Vargas, LC | 1 |
| Ribeiro, L | 1 |
| Busnello, JV | 1 |
| Kauer-Sant'Anna, M | 1 |
| Madruga, M | 1 |
| Quevedo, J | 1 |
| Busnello, EA | 1 |
| Kapczinski, F | 1 |
| Roy-Byrne, PP | 1 |
| Clary, CM | 1 |
| Miceli, RJ | 1 |
| Colucci, SV | 1 |
| Xu, Y | 1 |
| Grudzinski, AN | 1 |
| Dratcu, L | 1 |
| Allgulander, C | 1 |
| Dantendorfer, K | 1 |
| Knezevic, A | 1 |
| Maierhofer, D | 1 |
| Micev, V | 1 |
| Paunovic, VR | 1 |
| Timotijevic, I | 1 |
| Sarkar, N | 1 |
| Skoglund, L | 1 |
| Pemberton, SC | 1 |
| Strauss, WL | 1 |
| Unis, AS | 1 |
| Cowan, C | 1 |
| Dawson, G | 1 |
| Pohl, R | 1 |
| Balon, R | 1 |
| Galynker, I | 1 |
| McQuistion, H | 1 |
| Kahn, RS | 1 |
| Friedman, M | 1 |
| Korn, ML | 1 |
| Molcho, A | 1 |
| Botsis, AJ | 1 |
| Grosz, D | 1 |
| Chen, C | 1 |
| Plutchik, R | 1 |
| Brown, SL | 1 |
| van Praag, HM | 1 |
| Saran, A | 1 |
| Halaris, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615] | 44 participants (Actual) | Interventional | 2020-07-27 | Active, not recruiting | |||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
9 reviews available for fluoxetine and Panic Attacks
| Article | Year |
|---|---|
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipr | 2023 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placeb | 2010 |
[Panic attacks and panic disorder. Checklist for the diagnosis].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans | 1996 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodi | 1997 |
Antidepressants in panic disorder: clinical and preclinical mechanisms.
Topics: Antidepressive Agents; Clomipramine; Fluoxetine; Humans; Panic Disorder; Raphe Nuclei; Receptors, Se | 1998 |
Fluoxetine: therapeutic and undesirable effects.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bulimia; Child; Drug Interactions; Fluo | 1998 |
Current concepts in the treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Fluvoxamine | 1999 |
Clinical efficacy of reboxetine in major depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; | 2000 |
17 trials available for fluoxetine and Panic Attacks
| Article | Year |
|---|---|
Depression and comorbid panic in primary care patients.
Topics: Adult; Comorbidity; Depressive Disorder; Female; Fluoxetine; Humans; Longitudinal Studies; Male; Mid | 2010 |
Adverse events in PTSD patients taking fluoxetine.
Topics: Akathisia, Drug-Induced; Arousal; Fluoxetine; Humans; Panic Disorder; Prospective Studies; Single-Bl | 1995 |
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
Topics: Adolescent; Adult; Agoraphobia; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Panic Dis | 1995 |
Cognitive behavior therapy for treatment-refractory panic disorder.
Topics: Adult; Alprazolam; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluo | 1994 |
Use of low-dose fluoxetine in major depression and panic disorder.
Topics: Adult; Ambulatory Care; Comorbidity; Depressive Disorder; Drug Administration Schedule; Drug Toleran | 1993 |
Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; | 1997 |
The treatment of comorbid premature ejaculation and panic disorder with fluoxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Drug Administration Schedule; Ejaculation; Fl | 1997 |
Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
Topics: Adult; Anxiety; Benzamides; Blood Pressure; Female; Fluoxetine; Humans; Male; Moclobemide; Monoamine | 1997 |
Antipanic effect of fluoxetine measured by CO2 challenge test.
Topics: Adult; Antidepressive Agents, Second-Generation; Carbon Dioxide; Female; Fluoxetine; Humans; Lactic | 1998 |
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; M | 1998 |
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.
Topics: Adult; Benzamides; Double-Blind Method; Female; Fluoxetine; Headache; Humans; Male; Moclobemide; Mon | 1999 |
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder.
Topics: Adult; Agoraphobia; Comorbidity; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Ag | 1999 |
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Female; Fluoxetin | 1999 |
Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression.
Topics: Adult; Agoraphobia; Ambulatory Care; Antidepressive Agents; Combined Modality Therapy; Comorbidity; | 2000 |
Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.
Topics: Agoraphobia; Analysis of Variance; Data Interpretation, Statistical; Dose-Response Relationship, Dru | 2000 |
Mirtazapine versus fluoxetine in the treatment of panic disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Double-Blind Method; Fema | 2001 |
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Drug Administration Schedule; | 2001 |
44 other studies available for fluoxetine and Panic Attacks
| Article | Year |
|---|---|
Enhanced responsiveness to hypoxic panicogenic challenge in female rats in late diestrus is suppressed by short-term, low-dose fluoxetine: Involvement of the dorsal raphe nucleus and the dorsal periaqueductal gray.
Topics: Animals; Behavior, Animal; Diestrus; Disease Models, Animal; Dorsal Raphe Nucleus; Female; Fluoxetin | 2021 |
Effect of fluoxetine and psychotherapy on heart rate variability in children and adolescents diagnosed with panic disorder: 24-hour Holter monitoring study before and after treatment.
Topics: Adolescent; Anti-Anxiety Agents; Case-Control Studies; Child; Electrocardiography, Ambulatory; Fluox | 2019 |
Effects of the adjunctive treatment of antidepressants with opiorphin on a panic-like defensive response in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Drug Th | 2020 |
Evidence of a suffocation alarm system sensitive to clinically-effective treatments with the panicolytics clonazepam and fluoxetine.
Topics: Animals; Asphyxia; Clonazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Escape Reac | 2014 |
Molecular docking and panicolytic effect of 8-prenylnaringenin in the elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Dopamine Plasma Membrane Transport Proteins; Flavanones; Fluoxetine; M | 2014 |
Acute and chronic treatment with serotonin reuptake inhibitors exert opposite effects on respiration in rats: possible implications for panic disorder.
Topics: Animals; Drug Administration Schedule; Fluoxetine; Male; Panic Disorder; Paroxetine; Piperazines; Py | 2010 |
Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine.
Topics: Animals; Anti-Anxiety Agents; Fluoxetine; Male; Panic Disorder; Periaqueductal Gray; Rats; Rats, Wis | 2010 |
The panicolytic-like effect of fluoxetine in the elevated T-maze is mediated by serotonin-induced activation of endogenous opioids in the dorsal periaqueductal grey.
Topics: Animals; Antidepressive Agents, Second-Generation; Fluoxetine; Male; Maze Learning; Motor Activity; | 2012 |
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Diazepam; Dose-Resp | 2012 |
[Clinical significance of adrenoreactivity in patients with some paroxysmal disorders (panic attacks and migraine)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Citalopram; Diagnostic and Statistical Manual of Men | 2003 |
Different effects of selective serotonin reuptake inhibitors on a patient suffering from panic disorder.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Hypnotics and Sedatives; Male; Pa | 2004 |
Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices.
Topics: Adult; Agoraphobia; Anxiety; Benzodiazepines; Choice Behavior; Cognitive Behavioral Therapy; Combine | 2004 |
[The peculiarities of panic disorders determined by gender dimorphism].
Topics: Antidepressive Agents, Second-Generation; Beta Rhythm; Citalopram; Electroencephalography; Female; F | 2004 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal | 2005 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, | 2006 |
Tegaserod-related possible drug interactions.
Topics: Constipation; Drug Interactions; Female; Fluoxetine; Humans; Indoles; Panic Disorder; Serotonin Rece | 2007 |
Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants?
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Chronic Dis | 1995 |
Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder.
Topics: Clonidine; Female; Fluoxetine; Growth Hormone; Humans; Male; Panic Disorder; Psychiatric Status Rati | 1995 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; | 1994 |
Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Panic Disord | 1993 |
Migraine with typical aura associated with fluoxetine therapy: case report.
Topics: Agoraphobia; Fluoxetine; Functional Laterality; Humans; Male; Middle Aged; Migraine Disorders; Panic | 1993 |
Open prospective trial of fluoxetine for posttraumatic stress disorder.
Topics: Adult; Combat Disorders; Defense Mechanisms; Depressive Disorder; Fluoxetine; Humans; Male; Middle A | 1993 |
Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients.
Topics: Adrenal Cortex; Adult; Clonidine; Female; Fluoxetine; Humans; Hypothalamo-Hypophyseal System; Male; | 1995 |
Panic associated with combining fluoxetine and bupropion.
Topics: Adult; Bupropion; Depressive Disorder; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dru | 1996 |
Inability to cry during SRI treatment.
Topics: 1-Naphthylamine; Adult; Crying; Depressive Disorder; Emotions; Female; Fluoxetine; Humans; Obsessive | 1996 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Ther | 1997 |
Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder.
Topics: Adult; Clonidine; Female; Fluoxetine; Humans; Hydrocortisone; Male; Methoxyhydroxyphenylglycol; Nore | 1997 |
Single-voxel 1H-MRS investigation of brain metabolic changes during lactate-induced panic.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Female; Fluoxetine; Hu | 1997 |
Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
Topics: Adult; Cyclohexanols; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Panic Diso | 1998 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Fluoxetine for clomipramine withdrawal symptoms.
Topics: Adult; Clomipramine; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Male; Panic Disorder; Sub | 1999 |
Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues.
Topics: Adult; Anorexia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Complementary Ther | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fl | 1999 |
[Dyspnoea of a young male patient].
Topics: Adult; Antidepressive Agents, Second-Generation; Asthma; Diagnosis, Differential; Dyspnea; Fluoxetin | 1996 |
[Indications for antidepressive medication].
Topics: Antidepressive Agents; Citalopram; Fluoxetine; Humans; Panic Disorder; Sensitivity and Specificity | 1997 |
Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clo | 2001 |
The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
Topics: Adolescent; Adult; Cohort Studies; Cost Savings; Drug Costs; Emergency Service, Hospital; Female; Fl | 2001 |
Physical exercise: an adjunctive treatment for panic disorder?
Topics: Adult; Combined Modality Therapy; Exercise; Female; Fluoxetine; Fluvoxamine; Humans; Middle Aged; Pa | 2001 |
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Autistic Disorder; Brain; Brain Chemistry; Child; Child Development | 2002 |
Antidepressants, panic disorder, and PTSD.
Topics: Adult; Desipramine; Female; Fluoxetine; Humans; Panic Disorder; Stress Disorders, Post-Traumatic | 1992 |
Fluoxetine treatment of slow eating.
Topics: Adult; Feeding Behavior; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Panic Disorder | 1992 |
Suicide and violence associated with panic attacks.
Topics: Adult; Alprazolam; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; | 1992 |
Panic attack precipitated by fluoxetine.
Topics: Adult; Alprazolam; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Panic Disorder; Psychiat | 1989 |